With a Precision Dosing System (PDS) already helping thousands of patients with pain and spasticity, Infusyn is currently developing a breakthrough in the treatment of pulmonary arterial hypertension (PAH) that promises to significantly improve the lives of the estimated 50,000 patients suffering from the debilitating disease.